PGT-A实验室分类策略与诊断产出及后续临床结局相关
该回顾性队列研究分析了2015年至2023年间9630个PGT-A周期、40308枚囊胚的检测数据,涉及三家商业PGT-A实验室。结果显示,不同实验室的整倍体率和单整倍体胚胎移植活产率存在差异,实验室B与实验室A相比活产率更低(OR=0.71),提示整倍体率不能单独作为实验室性能的完整指标。
要点
- 不同PGT-A实验室的整倍体率随母亲年龄变化存在差异。
- 实验室B与实验室A相比,单整倍体胚胎移植活产率显著更低(OR=0.71)。
- 整倍体率与下游活产率不一致,需结合临床结局评估实验室性能。
核心结论
- PGT-A实验室分类策略与诊断产出及单整倍体胚胎移植活产率均相关。
- 整倍体率与活产率之间的不一致表明,仅凭整倍体率不能全面衡量实验室性能。
研究设计与样本
- 涉及三家商业PGT-A实验室:实验室A(n=18480)、实验室B(n=19261)、实验室C(n=2567)。
- 临床结局分析限于网络主诊所进行的7333例单整倍体胚胎移植。
主要发现
- 总体囊胚整倍体率为52.3%(21093/40308)。
- 与实验室A相比,实验室B在年轻患者中整倍体率及获得至少一枚整倍体胚胎的可能性更低,但在年龄>42岁患者中整倍体率更高。
- 实验室C在年龄<41岁患者中诊断产出持续较低。
- 7333例单整倍体胚胎移植的活产率分别为实验室A 49.8%、实验室B 41.6%、实验室C 50.7%。
- 调整母亲年龄、BMI、不孕指征、内膜准备和厚度、胚胎评级及活检日后,实验室B与实验室A相比活产几率更低(OR=0.71,95%CI:0.64-0.79;p<0.001),实验室C与实验室A相当(OR=1.08,95%CI:0.89-1.32;p=0.418)。
临床怎么用
- 选择PGT-A实验室时不应仅关注整倍体率,需结合单整倍体胚胎移植后的活产率等下游临床结局综合评估。
- 对于不同年龄患者,实验室分类策略对诊断产出的影响可能不同,临床解读结果时应考虑年龄因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether PGT-A laboratory was associated with diagnostic yield and live birth per single euploid embryo transfer. DESIGN: Retrospective cohort study. SUBJECTS: We analyzed a total of 9,630 PGT-A cycles performed between January 2015 and December 2023, comprising 40,308 blastocysts tested using trophectoderm biopsy and next generation sequencing. Three commercial PGT-A laboratories were utilized: Laboratory A (n = 18,480), Laboratory B (n = 19,261), and Laboratory C (n = 2,567). Clinical outcome analyses were restricted to 7,333 single euploid embryo transfers performed at the network's main clinic. EXPOSURE: PGT-A laboratory. MAIN OUTCOME MEASURES: Euploidy rate, likelihood of having at least one euploid embryo available for transfer, and live birth rate per single euploid embryo transfer. RESULTS: Overall, 52.3% (21,093/40,308) of blastocysts were diagnosed as euploid. Diagnostic yield differed between laboratories and varied according to maternal age. Compared with Laboratory A, Laboratory B had lower euploidy rates and a lower likelihood of obtaining at least one euploid embryo in younger patients, with higher euploidy rates observed among patients aged >42 years. Laboratory C had a consistently lower diagnostic yield in patients younger than 41 years. Among 7,333 single euploid embryo transfers performed at the main clinic, live birth rates per transfer were 49.8%, 41.6%, and 50.7% for Laboratories A, B, and C, respectively. After adjusting for maternal age, BMI, infertility indication, endometrial preparation and thickness, embryo grade, and biopsy day, Laboratory B remained associated with lower odds of live birth per single euploid embryo transfer compared to Laboratory A (OR=0.71, [95%CI: 0.64-0.79]; p<0.001), while Laboratory C was comparable (OR=1.08, [95%CI: 0.89-1.32]; p=0.418). CONCLUSION: PGT-A laboratory classification strategy was associated with both diagnostic yield and live birth per transfer. The discordance between these outcomes shows that euploidy rates alone do not provide a complete measure of laboratory performance and should be interpreted alongside downstream clinical outcomes.
引用
- Popovic M, Kalafat E, Sakkas D, et al. Preimplantation genetic testing laboratory classification strategies are associated with diagnostic yield and downstream clinical performance. Fertil Steril. 2026. PMID: 42854774. doi:10.1016/j.fertnstert.2026.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。